CN104844660A - 一种氟苯钌化合物及其制备方法和用途 - Google Patents
一种氟苯钌化合物及其制备方法和用途 Download PDFInfo
- Publication number
- CN104844660A CN104844660A CN201510153187.3A CN201510153187A CN104844660A CN 104844660 A CN104844660 A CN 104844660A CN 201510153187 A CN201510153187 A CN 201510153187A CN 104844660 A CN104844660 A CN 104844660A
- Authority
- CN
- China
- Prior art keywords
- ruthenium compound
- fluorobenzene
- ruthenium
- preparation
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 Fluorine benzene ruthenium Chemical compound 0.000 title claims abstract description 17
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 201000011510 cancer Diseases 0.000 claims abstract description 20
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 19
- 239000003814 drug Substances 0.000 claims abstract description 15
- 201000007270 liver cancer Diseases 0.000 claims abstract description 15
- 208000014018 liver neoplasm Diseases 0.000 claims abstract description 15
- 229960000616 diflunisal Drugs 0.000 claims abstract description 6
- CDKFOFSSPSYAFE-UHFFFAOYSA-N fluorobenzene ruthenium Chemical compound [Ru].FC1=CC=CC=C1 CDKFOFSSPSYAFE-UHFFFAOYSA-N 0.000 claims description 32
- 239000002904 solvent Substances 0.000 claims description 25
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 20
- BIXNGBXQRRXPLM-UHFFFAOYSA-K ruthenium(3+);trichloride;hydrate Chemical compound O.Cl[Ru](Cl)Cl BIXNGBXQRRXPLM-UHFFFAOYSA-K 0.000 claims description 15
- 230000001926 lymphatic effect Effects 0.000 claims description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 10
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 8
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 claims description 6
- VMZCDNSFRSVYKQ-UHFFFAOYSA-N 2-phenylacetyl chloride Chemical class ClC(=O)CC1=CC=CC=C1 VMZCDNSFRSVYKQ-UHFFFAOYSA-N 0.000 claims description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 5
- 238000002425 crystallisation Methods 0.000 claims description 5
- 230000008025 crystallization Effects 0.000 claims description 5
- 229960000935 dehydrated alcohol Drugs 0.000 claims description 5
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 claims description 5
- 238000004821 distillation Methods 0.000 claims description 5
- 238000001704 evaporation Methods 0.000 claims description 5
- 230000008020 evaporation Effects 0.000 claims description 5
- 239000012467 final product Substances 0.000 claims description 5
- 238000001556 precipitation Methods 0.000 claims description 5
- 238000000746 purification Methods 0.000 claims description 5
- 238000010992 reflux Methods 0.000 claims description 5
- 229910052707 ruthenium Inorganic materials 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- 238000005406 washing Methods 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 abstract description 15
- 230000000694 effects Effects 0.000 abstract description 9
- 229940079593 drug Drugs 0.000 abstract description 6
- 230000009471 action Effects 0.000 abstract description 4
- 230000005540 biological transmission Effects 0.000 abstract description 3
- 238000001727 in vivo Methods 0.000 abstract description 3
- 210000002751 lymph Anatomy 0.000 abstract description 3
- 238000010521 absorption reaction Methods 0.000 abstract description 2
- 239000002775 capsule Substances 0.000 abstract description 2
- 239000000839 emulsion Substances 0.000 abstract description 2
- 238000002347 injection Methods 0.000 abstract description 2
- 239000007924 injection Substances 0.000 abstract description 2
- 239000003826 tablet Substances 0.000 abstract description 2
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 239000008188 pellet Substances 0.000 abstract 1
- 230000035699 permeability Effects 0.000 abstract 1
- 239000000725 suspension Substances 0.000 abstract 1
- YKFLAYDHMOASIY-UHFFFAOYSA-N γ-terpinene Chemical compound CC(C)C1=CCC(C)=CC1 YKFLAYDHMOASIY-UHFFFAOYSA-N 0.000 description 16
- 239000000243 solution Substances 0.000 description 8
- 229910052731 fluorine Inorganic materials 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 125000001153 fluoro group Chemical group F* 0.000 description 4
- 230000000527 lymphocytic effect Effects 0.000 description 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 3
- 229940041181 antineoplastic drug Drugs 0.000 description 3
- 230000006837 decompression Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000011737 fluorine Substances 0.000 description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 230000000857 drug effect Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010073069 Hepatic cancer Diseases 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000037315 hyperhidrosis Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229910000765 intermetallic Inorganic materials 0.000 description 1
- 208000003243 intestinal obstruction Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 201000007450 intrahepatic cholangiocarcinoma Diseases 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 208000018555 lymphatic system disease Diseases 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 150000003304 ruthenium compounds Chemical class 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/0046—Ruthenium compounds
- C07F15/0053—Ruthenium compounds without a metal-carbon linkage
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510153187.3A CN104844660B (zh) | 2015-04-01 | 2015-04-01 | 一种氟苯钌化合物及其制备方法和用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510153187.3A CN104844660B (zh) | 2015-04-01 | 2015-04-01 | 一种氟苯钌化合物及其制备方法和用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104844660A true CN104844660A (zh) | 2015-08-19 |
CN104844660B CN104844660B (zh) | 2017-12-05 |
Family
ID=53844689
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510153187.3A Expired - Fee Related CN104844660B (zh) | 2015-04-01 | 2015-04-01 | 一种氟苯钌化合物及其制备方法和用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104844660B (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090312301A1 (en) * | 2006-05-09 | 2009-12-17 | Paul Joseph Dyson | Transition Metal Complexes for Inhibiting Resistance in the Treatment of Cancer and Metastasis |
CN104387422A (zh) * | 2014-10-28 | 2015-03-04 | 广西师范学院 | 一种叔丁氧乙酰基钌化合物及其制备方法和用途 |
-
2015
- 2015-04-01 CN CN201510153187.3A patent/CN104844660B/zh not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090312301A1 (en) * | 2006-05-09 | 2009-12-17 | Paul Joseph Dyson | Transition Metal Complexes for Inhibiting Resistance in the Treatment of Cancer and Metastasis |
CN104387422A (zh) * | 2014-10-28 | 2015-03-04 | 广西师范学院 | 一种叔丁氧乙酰基钌化合物及其制备方法和用途 |
Non-Patent Citations (2)
Title |
---|
Y.N. VASHISHT GOPAL等,: "Topoisomerase II antagonism and anticancer activity of coordinated derivatives of [RuCl2(C6H6)(dmso)]", 《ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS》 * |
陈锦灿等,: "抗癌性钌配合物[HL][trans-RuIIICl4L2](L=2-NH2-5-Me-STz)的水解机理", 《物理化学学报》 * |
Also Published As
Publication number | Publication date |
---|---|
CN104844660B (zh) | 2017-12-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103946231B (zh) | 齐墩果酸酰胺化衍生物、及其制备方法和应用 | |
CN100445288C (zh) | 银杏内酯b衍生物及其在制药中的应用 | |
CN104387389A (zh) | 1,2,3-三唑-黄酮类化合物-苦参碱三元轭联物和用途 | |
CN107417752A (zh) | 一类具有抗癌活性的化合物及其制备方法和应用 | |
CN106632383A (zh) | 莪术醇衍生物及其制备方法和在抗肿瘤药物中的应用 | |
CN107556361A (zh) | 裂环羽扇豆烷衍生物及其抗肿瘤用途 | |
CN104707148A (zh) | 一种用于抗肝癌的聚乙二醇改性甘草次酸和姜黄素复合物及其制备方法 | |
CN101830897A (zh) | 新型异喹啉类生物碱衍生物及其制备方法与应用 | |
CN106188209B (zh) | 一种兼具抗肿瘤和抗肿瘤转移活性的二甲双胍偶联物及其应用 | |
CN101402667B (zh) | 糖基化修饰的一氧化氮供体型齐墩果酸类化合物、其制备方法及用途 | |
CN108836937A (zh) | 顺铂纳米药物制剂、制备方法和应用 | |
Liu et al. | Preparation and pharmacodynamics of Niclosamide-hydroxypropyl-β-cyclodextrin inclusion complex | |
CN104844660A (zh) | 一种氟苯钌化合物及其制备方法和用途 | |
CN114042043B (zh) | 一种雷公藤甲素线粒体靶向脂质体及其应用 | |
CN105399794A (zh) | 罗汉果三萜皂甙及其盐和其制备方法、应用及包含该罗汉果三萜皂甙及其盐的药物组合物 | |
CN108690090A (zh) | 一种钌的Schiff碱配合物的制备方法及其抗肿瘤的应用 | |
CN104003968A (zh) | 天然产物3-prenyl Iuteolin类似物(Ⅰ)/(Ⅱ)及其制备方法和应用 | |
CN105541732B (zh) | 一种β‑拉帕醌衍生物及其制备方法和医药用途 | |
CN104055786B (zh) | 苜蓿酸-3-O-β-D-吡喃葡萄糖苷、苜蓿酸及其盐在制备防治肿瘤药物中的应用 | |
CN110423254B (zh) | 一种具有不对称单取代香豆素四价铂结构化合物、制备方法及其在制备抗肿瘤药物中的应用 | |
CN107200769A (zh) | 一种具有防治肿瘤转移作用的救必应酸衍生物 | |
Fang et al. | Self-Assembled Micellar Glutaminase Allosteric Inhibitor for Effective Therapeutic Intervention | |
CN104892721B (zh) | 一种新的19-脱甲基蟾毒内酯化合物及其在制备抗肿瘤药物制剂中的应用 | |
CN102775596B (zh) | 紫杉醇衍生物及其制备方法和用途 | |
CN104974135B (zh) | 靶向dna具有抗肿瘤活性的含萘二酰亚胺结构的塞来昔布衍生物、药物组合物及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
EXSB | Decision made by sipo to initiate substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20171026 Address after: 441000 Shengli Street, Hubei, Xiangyang, No. 182 Applicant after: The Sixth Construction Co., Ltd. of China National Chemical Engineering Corp. Address before: 430040, No. 31, Wuhuan Avenue, Wuhan, Hubei, Dongxihu (8) Applicant before: A Kangmeiya bio tech ltd, Wuhan |
|
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Cao Manying Inventor before: Zhang Hao Inventor before: Xiao Xiaoyang |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20171205 Termination date: 20200401 |